Navigation Links
Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer

GSK Announces Launch of Largest Ever Phase III Clinical Trial in Lung Cancer Treatment

PHILADELPHIA, June 05, 2007 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced final results of a Phase II proof-of-concept clinical trial of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3 positive patients with stage IB or II Non-Small Cell Lung Cancer (NSCLC). These data were presented at the 2007 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, [Abstract No: 7554]. Final trial analysis showed a 27% reduction in the relative risk of cancer recurrence following surgery in patients treated with the MAGE-A3 ASCI, compared to placebo.

"Final results from this trial confirm the positive interim results released last year at ASCO 2006, and support expanded testing of this novel cancer immunotherapy," said Paul A. Bunn Jr., M.D., James Dudley Endowed Professor of Oncology, Professor of Medicine and Director of the University of Colorado Cancer Center, Aurora, Colorado. "This approach represents a potentially momentous shift in the cancer treatment paradigm. I believe we have only just scratched the surface of what is possible and look forward to seeing the results of the Phase III trial in due course."

Based on these encouraging data, GSK also announced today the opening of patient recruitment to the randomized and controlled Phase III efficacy and safety trial for this novel cancer immunotherapy; the largest clinical trial ever conducted in lung cancer treatment. MAGE-A3 ASCI will be evaluated as adjuvant therapy in about 2,270 MAGE-A3 positive patients with completely resected stage IB, II or IIIA NSCLC.

GSK's ASCIs aim to stimulate the patient's own immune response to identify and attack cancer cells in a highly specific manner. This novel cancer immunotherapy is developed using tumor specific antigens, delivered as highly puri
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
2. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
3. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
4. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:7/31/2014)... , July 31, 2014 Rock Creek Pharmaceuticals, ... it has initiated the development of its lead molecule, ... that it has selected Quotient Clinical, The Translational Pharmaceutics ... (UK) to run its early development programs. ... Application (CTA) by the end of the third quarter ...
(Date:7/31/2014)... 2014  A substantial share of pharmacy and ... therapies are included in formularies—say patient support resources ... new Manhattan Research study, Taking the Pulse® ... that P&T committee members in hospitals, managed care ... set a high bar for these programs, requiring ...
(Date:7/31/2014)... Portugal , July 31, 2014 ... Cork, Ireland has successfully passed a pre-approval inspection ... The inspection, carried out by the FDA Consumer Safety Officer, ... planned, started on 21 st July and concluded on ... be compliant with the principles and guidelines of Good Manufacturing ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2
... College of American Pathologists Outlines Recommendations at Food and Drug ... , ... increasing importance of laboratory tests in diagnosing and treating disease, representatives ... the Food and Drug Administration (FDA) urging increased oversight of laboratory ...
... CHICAGO and PASADENA, Calif. , July 20 ... that Huntington Memorial Hospital has selected the Allscripts ... Exchange (HIE) that enables physicians, hospitals and other health care providers ... team approach to patient care, regardless of where they are located ...
Cached Medicine Technology:CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 2CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 3CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 4Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 2Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 3Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 4Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 5Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 6Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 7
(Date:8/1/2014)... (PRWEB) August 01, 2014 Transparency ... announced the addition of a comprehensive report on ... ‘Infusion System Market (Large Volume, Disposable, Syringe, Ambulatory ... Growth, Trends And Forecast, 2013 – 2019’ is ... http://www.transparencymarketresearch.com . , To begin with, the ...
(Date:8/1/2014)... HealthDay Reporter , THURDAY, July 31, 2014 (HealthDay ... cafeteria fare, a new study suggests. The new research ... fourth graders brought from home met three of five National ... similar to results of other studies of children,s packed lunches ... foods and beverages are more common than fruits, vegetables and ...
(Date:8/1/2014)... older women with asthma often have worse health outcomes, they ... new study. "There is no doubt that women over ... concluded Dr. James Sublett, an allergist and president-elect of the ... organization news release. In fact, the asthma death rate ... times higher than in other groups of people, the study,s ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 For the ... their Organic Cotton Farm & Fiber Report and the ... for the entire organic cotton supply chain resulting in ... Pepper, the organization’s Managing Director, reports, “We are looking ... farmers are the beginning of a long value chain ...
(Date:8/1/2014)... August 01, 2014 Did you know that ... Sarcoma Awareness Month is to raise awareness across the country ... options for, sarcoma. According to the American Cancer Society, nearly ... 2014, while 12,000 new soft tissue sarcomas will be diagnosed. ... sarcoma tumors as they are other kinds of cancer,” said ...
Breaking Medicine News(10 mins):Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 3Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 2Health News:Kids' Lunch Boxes Often Fall Short on Nutrition 3Health News:Older Women With Asthma Face Worse Health Outcomes 2Health News:Surveys Reveal the Top 10 Organic Cotton Users and the Top 10 Producing Countries 2Health News:July Was Sarcoma Awareness Month! 2Health News:July Was Sarcoma Awareness Month! 3Health News:July Was Sarcoma Awareness Month! 4
... Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a ... non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and ... provided a business update, and management reiterated its expectation ... completes the development and regulatory review of its lead ...
... ... ... is a critical piece of a healthy lifestyle, however, those who suffer from diabetes may ... of Sports Health: A Multidisciplinary Approach. Authors confirm that exercise can aid in diabetes treatment ...
... ... The Real Housewives of Orange County ,” Dr. Milind Ambe consulted with Lynne Curtin’s ... Orange County breast augmentation with the 19 year-old. , ... (Vocus) December 29, 2009 -- Newport Beach ...
... ... Texas, announced today that it has expanded its’ continuum of care with the addition of ... ... announced today that it has expanded its’ continuum of care to include Origins owned and ...
... , Department of Health Urges All Pennsylvanians ... federal Centers for Disease Control and Prevention, or CDC, has ... to Pennsylvania to date, the state Department of Health said ... certified providers, local health departments, and state health centers. ...
... have identified a role for enhanced activation of the ... either the TSC1 or the TSC2 protein. As indicated ... in an accompanying commentary, these data provide a rationale ... those with TSC-associated tumors. Tuberous sclerosis complex (TSC) ...
Cached Medicine News:Health News:Echo Therapeutics Provides Business Update 2Health News:Echo Therapeutics Provides Business Update 3Health News:Echo Therapeutics Provides Business Update 4Health News:Echo Therapeutics Provides Business Update 5Health News:Exercise May Reduce the Complications of Diabetes, According to Sports Health Journal Study 2Health News:Exercise May Reduce the Complications of Diabetes, According to Sports Health Journal Study 3Health News:Newport Beach Plastic Surgeon Educates About the Pros and Cons of Plastic Surgery 2Health News:Newport Beach Plastic Surgeon Educates About the Pros and Cons of Plastic Surgery 3Health News:Origins Recovery Centers Announces an Expansion of its Continuum of Care 2Health News:Origins Recovery Centers Announces an Expansion of its Continuum of Care 3
Micro-mini fiber optic light....
The MC-3 allows for simultaneous use of two lamps, with an additional built-in spare....
Xenon technology achieves a higher efficiency than halogen light sources. Consequently they provide more light....
Delivers one primary lamp and one backup lamp. The port accepts ACMI fiberoptic cables....
Medicine Products: